1887
Volume 2014, Issue 3
  • ISSN: 2305-7823
  • E-ISSN:

There is no abstract available for this article.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2014.37
2014-11-01
2019-10-22
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2014/3/gcsp.2014.37.html?itemId=/content/journals/10.5339/gcsp.2014.37&mimeType=html&fmt=ahah

References

  1. [1]. Assmann   G., , Schulte   H., , von Eckardstein   A., , Huang   Y. . High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. . Atherosclerosis . 1996; ;124: Suppl : S11– S20 .
    [Google Scholar]
  2. [2]. Wilkins   JT., , Ning   H., , Stone   NJ., , Criqui   MH., , Zhao   L., , Lloyd-jones   DM. . Coronary heart disease risks associated with high levels of HDL cholesterol. . J Am Hear Assoc . 2014; ;3: : e000519 .
    [Google Scholar]
  3. [3]. Kamanna   VS., , Kashyap   ML. . Mechanism of action of niacin. . Am J Cardiol . 2008; ;101: 8A : 20B– 26B .
    [Google Scholar]
  4. [4]. Barter   PJ., , Caulfield   M., , Eriksson   M., , Grundy   SM., , Kastelein   JJ., , Komajda   M., , Lopez-Sendon   J., , Mosca   L., , Tardif   JC., , Waters   DD., , Shear   CL., , Revkin   JH., , Buhr   KA., , Fisher   MR., , Tall   AR., , Brewer   B., , ILLUMINATE Investigators. . Effects of torcetrapib in patients at high risk for coronary events. . N Engl J Med . 2007; ;357: 21 : 2109– 2122 .
    [Google Scholar]
  5. [5]. Schwartz   G., , Chaitman   BBR., , Holme   IM., , Kallend   DD., , Leiter   LA., , Leitersdorf   E., , Mcmurray   JJV. . Effects of dalcetrapib in patients with a recent acute coronary syndrome. . N Engl J Med . 2012; ;367: : 2089– 2099 .
    [Google Scholar]
  6. [6]. HPS2-THRIVE Collaborative Group , Landray   MJ., , Haynes   R., , Hopewell   JC., , Parish   S., , Aung   T., , Tomson   J., , Wallendszus   K., , Craig   M., , Jiang   L., , Collins   R., , Armitage   J. . Effects of extended-release niacin with laropiprant in high-risk patients. . N Engl J Med . 2014; ;371: 3 : 203– 212 .
    [Google Scholar]
  7. [7]. AIM-HIGH Investigators., , Boden   WE., , Probstfield   JL., , Anderson   T., , Chaitman   BR., , Desvignes-Nickens   P., , Koprowicz   K., , McBride   R., , Teo   K., , Weintraub   W. . Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. . N Engl J Med . 2012; ;365: 24 : 2255– 2267 .
    [Google Scholar]
  8. [8]. Anderson   TJ., , Boden   WE., , Desvigne-Nickens   P., , Fleg   JL., , Kashyap   ML., , McBride   R., , Probstfield   JL., , AIM-HIGH Investigators. . Safety profile of extended-release niacin in the AIM-HIGH trial. . N Engl J Med . 2014; ;371: 3 : 288– 290 .
    [Google Scholar]
  9. [9]. Cannon   CP., , Braunwald   E., , McCabe   CH., , Rader   DJ., , Rouleau   JL., , Belder   R., , Joyal   SV., , Hill   KA., , Pfeffer   MA., , Skene   AM., , Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. . N Engl J Med . 2004; ;350: 15 : 1495– 1504 .
    [Google Scholar]
  10. [10]. Waters   DD., , Guyton   JR., , Herrington   DM., , McGowan   MP., , Wenger   NK., , Shear   C. . Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?.   Am J Cardiol . 2004; ;93: 2 : 154– 158 .
    [Google Scholar]
  11. [11]. Coronary Drug Project Research Group . Clofibrate and niacin in coronary heart disease. . JAMA . 1975; ;231: : 360– 381 .
    [Google Scholar]
  12. [12]. HPS2-THRIVE Collaborative Group., , Landray   MJ., , Haynes   R., , Hopewell   JC., , Parish   S., , Aung   T., , Tomson   J., , Wallendszus   K., , Craig   M., , Jiang   L., , Collins   R., , Armitage   J. . Effects of extended-release niacin with laropiprant in high-risk patients. . N Engl J Med . 2014; ;371: 3 : 203– 212 .
    [Google Scholar]
  13. [13]. Martin   SS., , Khokhar   AA., , May   HT., , Kulkarni   KR., , Blaha   MJ., , Joshi   PH., , Toth   PP., , Muhlestein   JB., , Anderson   JL., , Knight   S., , Li   Y., , Spertus   JA., , Jones   SR., , on behalf of the Lipoprotein Investigators Collaborative (LIC). . HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. . Eur Heart J . 2014; ; , pii: ehu264. http://dx.doi.org/10.1093/eurheartj/ ehu264 .
    [Google Scholar]
  14. [14]. Rosenson   RS., , Bryan Brewer   H Jr., , Sean   D., , Fayad   ZA., , Fuster   V., , Goldstein   J., , Hellerstein   M., , Jiang   X-C., , Phillips   MC., , Rader   DJ., , Remaley   AT., , Rothblat   GH., , Tall   AR., , Yvan-Charvet   L. . Contemporary reviews in cardiovascular medicine: Cholesterol efflux and atheroprotection. . Circulation . 2012; ;125: : 1905– 1919 .
    [Google Scholar]
  15. [15]. Rubins   HB., , Robins   SJ., , Collins   D., , Fye   CL., , Anderson   JW., , Elam   MB., , Faas   FH., , Linares   E., , Schaefer   EJ., , Schectman   G., , Wilt   TJ., , Wittes   J. . Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. . N Engl J Med . 1999; ;341: : 410– 418 .
    [Google Scholar]
  16. [16]. Stone   NJ., , Robinson   JG., , Lichtenstein   AH., , Bairey Merz   CN., , Blum   CB., , Eckel   RH., , Goldberg   AC., , Gordon   D., , Levy   D., , Lloyd-Jones   DM., , McBride   P., , Schwartz   JS., , Shero   ST., , Smith   SC Jr., , Watson   K., , Wilson   PW., , American College of Cardiology/American Heart Association Task Force on Practice Guidelines. . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. . J Am Coll Cardiol . 2014; ;63: : 2889– 2934 .
    [Google Scholar]
  17. [17]. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute., , Crosby   J., , Peloso   GM., , Auer   PL., , Crosslin   DR., , Stitziel   NO., , Lange   LA., , Lu   Y., , Tang   ZZ., , Zhang   H., , Hindy   G., , Masca   N., , Stirrups   K., , Kanoni   S., , Do   R., , Jun   G., , Hu   Y., , Kang   HM., , Xue   C., , Goel   A., , Farrall   M., , Duga   S., , Merlini   PA., , Asselta   R., , Girelli   D., , Olivieri   O., , Martinelli   N., , Yin   W., , Reilly   D., , Speliotes   E., , Fox   CS., , Hveem   K., , Holmen   OL., , Nikpay   M., , Farlow   DN., , Assimes   TL., , Franceschini   N., , Robinson   J., , North   KE., , Martin   LW., , DePristo   M., , Gupta   N., , Escher   SA., , Jansson   JH., , Van Zuydam   N., , Palmer   CN., , Wareham   N., , Koch   W., , Meitinger   T., , Peters   A., , Lieb   W., , Erbel   R., , Konig   IR., , Kruppa   J., , Degenhardt   F., , Gottesman   O., , Bottinger   EP., , O'Donnell   CJ., , Psaty   BM., , Ballantyne   CM., , Abecasis   G., , Ordovas   JM., , Melander   O., , Watkins   H., , Orho-Melander   M., , Ardissino   D., , Loos   RJ., , McPherson   R., , Willer   CJ., , Erdmann   J., , Hall   AS., , Samani   NJ., , Deloukas   P., , Schunkert   H., , Wilson   JG., , Kooperberg   C., , Rich   SS., , Tracy   RP., , Lin   DY., , Altshuler   D., , Gabriel   S., , Nickerson   DA., , Jarvik   GP., , Cupples   LA., , Reiner   AP., , Boerwinkle   E., , Kathiresan   S. . Loss-of-function mutations in APOC3, triglycerides, and coronary disease. . N Engl J Med . 2014; ;   371 : 22– 31 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2014.37
Loading
/content/journals/10.5339/gcsp.2014.37
Loading

Data & Media loading...

  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error